Mi-ran Han Chang-Hoo Lee So-Yeon Jeon Ho-Young Yhim Na-Ri Lee Jae-Yong Kwak Ho-Sung Park Eun-Kee Song

Abstract

Pembrolizumab, an immune checkpoint inhibitor (ICI) targeting the programmed cell death protein 1 (PD-1) receptor on T cells, enhances the immune system’s ability to recognize and attack cancer cells. However, immune-related adverse events (irAEs) may arise, necessitating careful monitoring during treatment. Here, we present the case of a 47-year-old woman who developed multiple irAEs following pembrolizumab therapy. Initially diagnosed with Stage IIIB non-small cell lung cancer, she underwent chemotherapy followed by concurrent chemoradiotherapy. After two years of monitoring, progression of disease was observed, and pembrolizumab was initiated as second-line chemotherapy. Shortly thereafter, she presented with left-sided ptosis and weakness in both upper and lower extremities. Diagnostic evaluation, including a tensilon test and laboratory findings, confirmed with myositis, hepatitis, and myasthenia gravis. Treatment with steroids and neostigmine led to marked clinical improvement. Two months later, the patient developed additional dermatological symptoms, including rash and pruritus. Skin biopsy confirmed a diagnosis of pityriasis lichenoides. she is currently receiving antihistamines therapy, with no further exacerbation. This case underscores the importance of recognizing and promptly managing irAEs associated with ICIs to ensure patient safety and treatment efficacy.

##plugins.themes.bootstrap3.article.details##

Keywords

Pembrolizumab, Immune-related adverse events (irAE), Immune-mediated hepatitis, Myasthenia gravis, Myositis, Pityriasis lichenoides chronica (PLC), Non-small cell lung cancer (NSCLC)

References
1. Kwok G, Yau TC, Chiu JW, Tse E, Kwong YL. Pembrolizumab (Keytruda). Hum Vaccin Immunother. 2016 Nov;12(11):2777-2789. doi: 10.1080/21645515.2016.1199310. PMID: 27398650; PMCID: PMC5137544.
2. Zhou YJ, Li G, Wang J, et al. PD-L1: expression regulation. Blood Sci. 2023 Jan 13;5(2):77-91. doi: 10.1097/BS9.0000000000000149. PMID: 37228770; PMCID: PMC10205351.
3. Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016 Nov 10;375(19):1823-1833. doi: 10.1056/NEJMoa1606774. PMID: 27718847.
4. Buchbinder EI, Desai A. CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition. Am J Clin Oncol. 2016 Feb;39(1):98-106. doi: 10.1097/COC.0000000000000239. PMID: 26558876; PMCID: PMC4892769.
5. Ramos-Casals M, Brahmer JR, Callahan MK, et al. Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers. 2020 May 7;6(1):38. doi: 10.1038/s41572-020-0160-6. PMID: 32382051; PMCID: PMC9728094.
6. Das S, Johnson DB. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J Immunother Cancer. 2019 Nov 15;7(1):306. doi: 10.1186/s40425-019-0805-8. PMID: 31730012; PMCID: PMC6858629.
7. Alissafi T, Hatzioannou A, Legaki AI, Varveri A, Verginis P. Balancing cancer immunotherapy and immune-related adverse events: The emerging role of regulatory T cells. J Autoimmun. 2019 Nov;104:102310. doi: 10.1016/j.jaut.2019.102310. PMID: 31421963.
8. Postow MA, Sidlow R, Hellmann MD. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. N Engl J Med. 2018 Jan 11;378(2):158-168. doi: 10.1056/NEJMra1703481. PMID: 29320654.
9. Khalid F, Gupta R, Gor R, et al. Neurological Adverse Effects of Immune Checkpoint Inhibitors and Chimeric Antigen Receptor T-Cell Therapy. World J Oncol. 2023 Apr;14(2):109-118. doi: 10.14740/wjon1575. Epub 2023 Apr 30. PMID: 37188042; PMCID: PMC10181423.
10. Huang YT, Chen YP, Lin WC, Su WC, Sun YT. Immune Checkpoint Inhibitor-Induced Myasthenia Gravis. Front Neurol. 2020 Jul 16;11:634. doi: 10.3389/fneur.2020.00634. PMID: 32765397; PMCID: PMC7378376.
11. Gilhus NE. Myasthenia Gravis. N Engl J Med. 2016 Dec 29;375(26):2570-2581. doi: 10.1056/NEJMra1602678. PMID: 28029925.
12. Geller L, Antonov NK, Lauren CT, Morel KD, Garzon MC. Pityriasis Lichenoides in Childhood: Review of Clinical Presentation and Treatment Options. Pediatr Dermatol. 2015 Sep-Oct;32(5):579-92. doi: 10.1111/pde.12581. Epub 2015 Mar 26. PMID: 25816855.
How to Cite
Han, M.- ran, Lee, C.-H., Jeon, S.-Y., Yhim, H.-Y., Lee, N.-R., Kwak, J.-Y., Park, H.-S., & Song, E.-K. (2025). Pembrolizumab-induced simultaneous and multiple immune-related adverse events including myasthenia gravis, myositis, hepatitis, and pityriasis lichenoides in a non-small cell lung cancer patient. Archive of Clinical Cases, 12(1), 17-21. https://doi.org/10.22551/2025.46.1201.10306
Section
Case Reports

How to Cite

Han, M.- ran, Lee, C.-H., Jeon, S.-Y., Yhim, H.-Y., Lee, N.-R., Kwak, J.-Y., Park, H.-S., & Song, E.-K. (2025). Pembrolizumab-induced simultaneous and multiple immune-related adverse events including myasthenia gravis, myositis, hepatitis, and pityriasis lichenoides in a non-small cell lung cancer patient. Archive of Clinical Cases, 12(1), 17-21. https://doi.org/10.22551/2025.46.1201.10306